 BOSTON, April 28, 2021 GLOBE NEWSWIRE -- Inozyme Pharma, Inc. Nasdaq: INZY, a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization disorders, today announced that preclinical data from a study examining INZ-701 for the potential treatment for ABCC6 DeficiencyPseudoxanthoma elasticum PXE will be presented at the following upcoming medical conferences: 